Allermi

Allermi is a direct-to-consumer telehealth company focused on nasal allergies (rhinitis, also called hay fever). Patients complete a medical history and symptom questionnaire through a secure online portal, which is reviewed by the company's allergists; if a prescription is deemed appropriate and safe, a compounded "Super Spray" is prepared with up to four active ingredients at specified dosages and mailed to the patient. The advertised ingredient set includes azelastine (antihistamine), ipratropium (for runny nose and post-nasal drip), triamcinolone (corticosteroid anti-inflammatory) and micro-dosed oxymetazoline (decongestant). Treatment is limited to rhinitis; the company states it does not currently treat other conditions and treats patients aged 18 and older in select US states.

The service is sold as a kit that bundles the custom prescription spray, a saline "Salinity Spray," an online allergist consultation and ongoing messaging access to a medical care team. Patients can request formula changes at any time; if the care team agrees, a revised prescription is sent to the pharmacy within 48 hours. The company positions its multi-ingredient approach against single-ingredient over-the-counter products such as Flonase, Afrin and Astepro, citing 53 randomized controlled studies and 18+ peer-reviewed publications as support for its ingredients and combination approach.

Business model

Direct-to-consumer subscription-style sale of a prescription product bundled with telehealth consultation and unlimited care-team messaging, fulfilled by mail. Insurance is not accepted; purchases are paid out of pocket and stated to be eligible as HSA/FSA health expenses.

Product and service fees paid directly by patients. The kit is listed at $95 total ($60 Super Spray, $10 salinity spray, $25 consultation) with a promotional price of $45 including a free saline spray and free consultation, plus a free five-day sample offer.

Traction

The company reports more than 100,000 patients treated, over 14,000 five-star verified reviews with a 4.7/5 average rating, and that over 90% of patients experienced superior relief compared with previous allergy solutions, with 90% reporting nearly complete or complete relief of nasal symptoms.